İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2025 · article

Nusinersen for children with type I spinal muscular atrophy: 4 years' clinical experience in Turkish cohort

ISSN1664-2295
YÖKSİS OpenAlex Açık erişim · gold Üst %10
Yıl2025
Atıf5OpenAlex
Yüzdelik%92,5
FWCI3,531,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q2

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıFRONTIERS IN NEUROLOGY
  • Katalog eşleşmesi (ISSN)Frontiers in Neurology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Background: SMA Type 1 is the most severe form of spinal muscular atrophy with early symptom onset, limited motor development, and poor prognosis. Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years. Methods: This prospective, non-interventional study included 310 patients with genetically confirmed spinal muscular atrophy at 24 pediatric neurology centers in Turkey. Patients treated with nusinersen were divided into five age-based cohorts at treatment initiation: Cohort A (0-3 months), Cohort B (4-6 months), Cohort C (7-12 months), Cohort D (13-24 months), and Cohort E (>24 months). Efficacy was assessed using the CHOP-INTEND and WHO Motor Milestone Scale. This study also analyzed the respiratory support needs, gastrostomy requirements, and mortality rates across cohorts. Results: Patients treated before 12 months of age showed the most significant improvements in motor milestones, with 58.7% of Cohort A achieving independent sitting. CHOP-INTEND scores increased notably in all cohorts, with the largest improvement observed in Cohort A (93.5%). Ventilator and gastrostomy requirements decreased in the early treated cohorts. Adverse events were rare, with one discontinuation due to hydrocephalus. The overall mortality rate was 21.3%, with most of the deaths occurring within the first year. Interpretation: Nusinersen treatment initiated before 12 months of age, especially before 3 months of age, yielded the most favorable motor outcomes in patients with SMA type 1. Early initiation is associated with improved motor milestones and reduced need for ventilatory support. However, no significant improvements were observed in the bulbar function or in patients requiring extensive respiratory support.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

5atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 7 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2026 Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from TurkeyAtıf 0 · OpenAlex
  2. 2026 Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from Turkey.Atıf 0 · OpenAlex
  3. 2026 Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from TurkeyAtıf 0 · OpenAlex
  4. 2026 Effects of Newborn Screening and Nusinersen on Survival and Functional Outcomes in Spinal Muscular Atrophy with Two SMN2 Copies: A Nationwide Multicentre Real-world Study from TurkeyAtıf 0 · OpenAlex
  5. 2026 Urine protein/osmolality and creatinine/osmolality ratios for assessing proteinuria and motor function in children with spinal muscular atrophyAtıf 0 · OpenAlex
  6. 2026 Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from TurkeyAtıf 0 · OpenAlex
  7. 2026 Effects of newborn screening and nusinersen on survival and functional outcomes in spinal muscular atrophy with two SMN2 copies: A nationwide multicentre real-world study from TurkeyAtıf 0 · OpenAlex

Yazarlar

11
  1. ÖMER BEKTAŞ 1
  2. MURAT GÜLŞEN 2
  3. ONUR BURAK DURSUN 3
  4. DENİZ YÜKSEL 4
  5. ERCAN DEMİR 5
  6. SEMA SALTIK 6
  7. KÜRŞAT BORA ÇARMAN ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ 7
  8. HÜSEYİN TAN 8
  9. MUSTAFA KÖMÜR 9
  10. BÜLENT KARA 10
  11. AYCAN ÜNALP 11